Hydrochlorothiazide (HCTZ), one of the most widely prescribed antihypertensive diuretics worldwide, may raise a patient's risk of developing skin cancer, according to a report published by Medscape.

The report centers on growing evidence that HCTZ, a sulfonamide-derived thiazide diuretic, has photosensitizing properties. When skin is exposed to ultraviolet radiation, the drug can act as a photosensitizer, a mechanism researchers have implicated in the elevated incidence of cutaneous malignancies observed among long-term users.

The concern is not new to dermatology. Regulatory agencies in Europe have previously reviewed the association, and epidemiologic studies have pointed to a dose-dependent relationship between cumulative HCTZ exposure and risk of non-melanoma skin cancer, particularly squamous cell carcinoma. The Medscape report brings the issue back to the forefront for prescribers who manage patients on chronic antihypertensive therapy.

For dermatologists, the clinical implications are concrete. Patients on long-term HCTZ therapy represent a cohort that may benefit from more vigilant skin cancer screening, structured sun-protection counseling, and documentation of medication history during full-body skin examinations. The report encourages clinicians to consider the totality of a patient's photosensitizing exposures — including other medications with known photosensitizing potential — when stratifying skin cancer risk.

The stakes are significant given the drug's reach. HCTZ remains a first-line agent for hypertension in many treatment guidelines, and millions of patients take it chronically, often for decades. Any attributable increase in skin cancer incidence, even a modest one at the individual level, translates into a meaningful public health signal at the population scale.

At the same time, the report does not call for clinicians to abandon the drug. Hypertension control carries its own well-established benefits for cardiovascular and cerebrovascular outcomes. Instead, the message is one of risk awareness and shared decision-making: clinicians should know which of their patients are on HCTZ, counsel those patients about sun protection, and ensure they receive appropriate skin surveillance.

For dermatology practices, the report suggests several actionable steps. Front-desk intake and electronic health record workflows can capture thiazide use as part of the standard medication reconciliation. High-cumulative-dose patients — those with years of continuous HCTZ exposure — warrant particular attention during total-body skin exams, given the dose-response pattern described in the literature.

The intersection of systemic pharmacology and cutaneous oncology continues to sharpen. As real-world data on drug-induced photosensitivity and skin cancer risk accumulate, dermatologists can expect clearer guidance on which medication histories should trigger intensified screening protocols and how to coordinate medication adjustments with prescribing physicians.